ATE273714T1 - Topische zusammensetzungen zur prostaglandin e1 abgabe - Google Patents

Topische zusammensetzungen zur prostaglandin e1 abgabe

Info

Publication number: ATE273714T1
Authority: AT; Austria
Prior art keywords: prostaglandin; composition; delivery; aliphatic; mixture
Prior art date: 1997-11-05

Application number

AT99923024T

Other languages

English (en)

Inventor

James L Yeager

Nadir Buyuktimkin

Servet Buyuktimkin

Original Assignee

Nexmed Holdings Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-05

Filing date

1999-05-13

Publication date

2004-09-15

1999-05-13 Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc

2004-09-15 Application granted granted Critical

2004-09-15 Publication of ATE273714T1 publication Critical patent/ATE273714T1/de

Links

239000000203 mixture Substances 0.000 title abstract 7
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title abstract 3
229960000711 alprostadil Drugs 0.000 title abstract 3
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title abstract 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 3
230000000699 topical effect Effects 0.000 title abstract 2
125000001931 aliphatic group Chemical group 0.000 abstract 2
239000007853 buffer solution Substances 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 2
150000002634 lipophilic molecules Chemical class 0.000 abstract 2
239000003961 penetration enhancing agent Substances 0.000 abstract 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 abstract 1
-1 N,N-disubstituted amino Chemical group 0.000 abstract 1
230000002378 acidificating effect Effects 0.000 abstract 1
150000004676 glycans Chemical class 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Reproductive Health (AREA)
Oil, Petroleum & Natural Gas (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99923024T 1997-11-05 1999-05-13 Topische zusammensetzungen zur prostaglandin e1 abgabe ATE273714T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/964,509 US6046244A (en)	1997-11-05	1997-11-05	Topical compositions for prostaglandin E1 delivery
PCT/US1999/010596 WO2000069469A1 (en)	1997-11-05	1999-05-13	Topical compositions for prostaglandin e1 delivery

Publications (1)

Publication Number	Publication Date
ATE273714T1 true ATE273714T1 (de)	2004-09-15

Family

ID=25508632

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT98957603T ATE455535T1 (de)	1997-11-05	1998-11-05	Topische zusammensetzungen zur verabreichung von prostaglandin e1
AT99923024T ATE273714T1 (de)	1997-11-05	1999-05-13	Topische zusammensetzungen zur prostaglandin e1 abgabe

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT98957603T ATE455535T1 (de)	1997-11-05	1998-11-05	Topische zusammensetzungen zur verabreichung von prostaglandin e1

Country Status (20)

Country	Link
US (1)	US6046244A (de)
EP (2)	EP1028708B1 (de)
JP (2)	JP4491560B2 (de)
KR (2)	KR100576986B1 (de)
CN (2)	CN1191060C (de)
AT (2)	ATE455535T1 (de)
AU (1)	AU757086B2 (de)
BR (2)	BR9813945A (de)
CA (2)	CA2309165A1 (de)
DE (2)	DE69841463D1 (de)
DK (2)	DK1028708T3 (de)
ES (2)	ES2338389T3 (de)
HK (1)	HK1044289B (de)
HU (1)	HU230300B1 (de)
IL (3)	IL135914A0 (de)
MX (1)	MXPA01011560A (de)
PT (1)	PT1178833E (de)
TR (2)	TR200002158T2 (de)
TW (1)	TW443933B (de)
WO (2)	WO1999022714A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR1002847B (el)	1997-05-06	1998-01-27		Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US7914814B2 (en)	1997-09-17	2011-03-29	Strategic Science & Technologies, Llc	Topical delivery of arginine of cause beneficial effects
US7629384B2 (en)	1997-09-17	2009-12-08	Strategic Science & Technologies, Llc	Topical delivery of L-arginine to cause beneficial effects
US6046244A (en) *	1997-11-05	2000-04-04	Nexmed Holdings, Inc.	Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) *	1997-11-05	2002-07-02	Nexmed Holdings, Inc.	Topical compositions containing prostaglandin E1
GR1003199B (el) *	1998-08-14	1999-09-01		Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6486207B2 (en) *	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) *	1998-12-10	2004-11-30	Nexmed (Holdings) , Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) *	1998-12-10	2007-08-16	Nexmed Holdings, Inc.	Methods of treatment for female sexual arousal disorder
EA008720B1 (ru) *	1998-12-10	2007-06-29	Нексмед (Холдингс), Инк.	Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US20050004226A1 (en) *	1998-12-10	2005-01-06	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
AU3713600A (en)	1999-03-01	2000-09-21	Nitromed, Inc.	Nitrosated and nitrosylated prostaglandins, compositions and metods of use
US6693135B2 (en) *	2000-01-10	2004-02-17	Nexmed (Holdings) Incorporated	Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) *	2000-01-10	2001-11-27	Nexmed (Holdings) Inc.	Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) *	2000-01-10	2006-09-12	Nexmed Holdings, Inc.	Prostaglandin compositions and methods of treatment for male erectile dysfunction
KR100402334B1 (ko) *	2000-06-23	2003-10-22	환인제약 주식회사	알프로스타딜 외용제
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
KR100373540B1 (ko) *	2000-09-20	2003-02-25	최한곤	프로스타글란딘 ｅ1용 요도좌제 조성물
KR100810404B1 (ko) *	2001-12-18	2008-03-04	환인제약 주식회사	알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물
US20050159485A1 (en) *	2002-01-04	2005-07-21	Jost-Price Edward R.	Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases
KR20040082431A (ko) *	2002-02-15	2004-09-24	넥스메드 홀딩스 인코포레이티드	발기기능장애를 치료하기 위한 프로스타글란딘 조성물
WO2003092617A2 (en) *	2002-05-03	2003-11-13	Combinatorx, Incorporated	Combinations for the treatment of inflammatory skin disorders
WO2004007786A2 (en) *	2002-07-17	2004-01-22	Liquidmetal Technologies	Method of making dense composites of bulk-solidifying amorphous alloys and articles thereof
GB0222522D0 (en)	2002-09-27	2002-11-06	Controlled Therapeutics Sct	Water-swellable polymers
US6841574B2 (en) *	2003-01-03	2005-01-11	Nexmed Holdings, Inc.	Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) *	2003-01-03	2005-08-18	Mo Y. J.	Topical stabilized prostaglandin E compound dosage forms
CN1774237A (zh) *	2003-03-21	2006-05-17	尼克美制药控股有限公司	前列腺素组合物及其促进血管生成的方法
CA2519707A1 (en) *	2003-03-21	2004-10-07	Nexmed (Holdings), Inc.	Prostaglandin compositions for the treatment of erectile dysfunction
DK2106805T3 (da) *	2003-03-21	2011-08-15	Nexmed Holdings Inc	Antifungal neglelak og anvendelsesmetode
EP1608378A1 (de) *	2003-04-02	2005-12-28	Nexmed (Holdings), Inc.	Prostaglandin-zusammensetzungen und ihre verwendung zur behandlung von vasospasmus
US9226909B2 (en)	2004-04-19	2016-01-05	Strategic Science & Technologies, Llc	Beneficial effects of increasing local blood flow
EP2420241A1 (de) *	2004-04-19	2012-02-22	Strategic Science & Technologies, LLC	Transdermale Abgabe von vorteilhaften Substanzen; die von einem feindlichen biophysischen Umfeld beeinflusst werden
AU2012201048B2 (en) *	2004-04-19	2013-06-06	Strategic Science & Technologies, Llc	Transdermal delivery of beneficial substances effected by a hostile biophysical environment
JP2007532697A (ja)	2004-04-19	2007-11-15	ストラテジックサイエンスアンドテクノロジーズ，エルエルシー	局所的血流増大の有益な効果
US20050276865A1 (en) *	2004-05-20	2005-12-15	Servet Buyuktimkin	Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
GB0417401D0 (en) *	2004-08-05	2004-09-08	Controlled Therapeutics Sct	Stabilised prostaglandin composition
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
RS52671B (sr)	2005-10-12	2013-06-28	Unimed Pharmaceuticals Llc	Poboljšani gel testosterona i postupak korišćenja
US8358785B2 (en) *	2006-05-30	2013-01-22	Siemens Audiologische Technik Gmbh	Hearing system with wideband pulse transmitter
GB0613333D0 (en)	2006-07-05	2006-08-16	Controlled Therapeutics Sct	Hydrophilic polyurethane compositions
GB0613638D0 (en)	2006-07-08	2006-08-16	Controlled Therapeutics Sct	Polyurethane elastomers
US7560489B2 (en) *	2006-10-11	2009-07-14	Nexmed Holdings, Inc.	Stabilized prostaglandin E composition
GB0620685D0 (en)	2006-10-18	2006-11-29	Controlled Therapeutics Sct	Bioresorbable polymers
CA2739376A1 (en)	2008-10-03	2010-04-08	Nexmed Holdings, Inc.	Stabilized composition for treating psoriasis
US12138268B2 (en)	2009-06-24	2024-11-12	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
EP2445493A1 (de)	2009-06-24	2012-05-02	Strategic Science & Technologies, LLC	Topische zusammensetzung mit naproxen
US11684624B2 (en)	2009-06-24	2023-06-27	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
CN102481275B (zh)	2009-06-24	2014-07-23	战略科学技术有限公司	含有布洛芬的表面组合物
CN102858158A (zh) *	2010-05-04	2013-01-02	尼克美控股公司	小分子治疗剂的组合物
CN103237785A (zh) *	2010-09-24	2013-08-07	尼克美控股公司	增强的经颊药物递送系统和组合物
CN103442723A (zh)	2010-12-29	2013-12-11	战略科学与技术有限责任公司	治疗变态反应和其它适应症的系统和方法
EP2658551B1 (de)	2010-12-29	2020-07-01	Strategic Science & Technologies, LLC	Behandlung von erektionsstörungen und anderen indikationen
WO2012139033A1 (en)	2011-04-07	2012-10-11	Nexmed Holdings, Inc.	Methods and compositions for treating raynaud's disease
ITRM20120036A1 (it) *	2012-02-02	2013-08-03	Robert Davis Steigerwalt Jr	Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
WO2015172102A1 (en) *	2014-05-09	2015-11-12	Nexmed Holdings, Inc.	Treating female sexual arousal disorder and related symptoms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5948409A (ja) *	1982-09-10	1984-03-19	Teikoku Seiyaku Kk	矯正的歯牙移動促進剤
DK243084A (da) *	1983-05-26	1984-11-27	Takeda Chemical Industries Ltd	Perkutane farmaceutiske praeparater til udvortes brug
GB8416638D0 (en) *	1984-06-29	1984-08-01	Beecham Group Plc	Topical treatment and composition
US4732892A (en) *	1985-07-12	1988-03-22	American Home Products Corporation	L-α-amino acids as transdermal penetration enhancers
US4771004A (en) *	1986-08-29	1988-09-13	Iprx, Inc.	Method for in vitro determination of transdermal absorption
US4808414A (en) *	1986-09-29	1989-02-28	Nelson Research & Development Co.	Amide penetration enhancers for transdermal delivery of systemic agents
US5219885A (en) *	1987-02-16	1993-06-15	Froelich Juergen	Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4865848A (en) *	1987-02-26	1989-09-12	Alza Corporation	Skin permeation enhancer compositions using sucrose esters
EP0302147A1 (de) *	1987-08-03	1989-02-08	The Procter & Gamble Company	Topische Bräunungsmittel
US5082866A (en) *	1988-06-01	1992-01-21	Odontex, Inc.	Biodegradable absorption enhancers
US4980378A (en) *	1988-06-01	1990-12-25	Odontex, Inc.	Biodegradable absorption enhancers
US5534260A (en) *	1989-02-23	1996-07-09	University Of Utah	Percutaneous drug delivery system
US4973468A (en) *	1989-03-22	1990-11-27	Cygnus Research Corporation	Skin permeation enhancer compositions
JP3202777B2 (ja) *	1992-01-24	2001-08-27	リンテック株式会社	経皮吸収促進剤及びテープ製剤
US5380760A (en) *	1993-11-19	1995-01-10	Minnesota Mining And Manufacturing Company	Transdermal prostaglandin composition
ATE399004T1 (de) *	1993-12-13	2008-07-15	Avanir Pharmaceuticals	Formulierungen aus c-20 bis c-28 alkoholen und saccharoseestern
US6046244A (en) *	1997-11-05	2000-04-04	Nexmed Holdings, Inc.	Topical compositions for prostaglandin E1 delivery

1997
- 1997-11-05 US US08/964,509 patent/US6046244A/en not_active Expired - Lifetime
1998
- 1998-11-05 DK DK98957603.8T patent/DK1028708T3/da active
- 1998-11-05 CN CNB988129159A patent/CN1191060C/zh not_active Expired - Lifetime
- 1998-11-05 CA CA002309165A patent/CA2309165A1/en not_active Abandoned
- 1998-11-05 WO PCT/US1998/023576 patent/WO1999022714A1/en not_active Ceased
- 1998-11-05 BR BR9813945-2A patent/BR9813945A/pt not_active Application Discontinuation
- 1998-11-05 IL IL13591498A patent/IL135914A0/xx not_active IP Right Cessation
- 1998-11-05 JP JP2000518648A patent/JP4491560B2/ja not_active Expired - Lifetime
- 1998-11-05 TR TR2000/02158T patent/TR200002158T2/xx unknown
- 1998-11-05 EP EP98957603A patent/EP1028708B1/de not_active Expired - Lifetime
- 1998-11-05 DE DE69841463T patent/DE69841463D1/de not_active Expired - Lifetime
- 1998-11-05 KR KR1020007004907A patent/KR100576986B1/ko not_active Expired - Lifetime
- 1998-11-05 AT AT98957603T patent/ATE455535T1/de active
- 1998-11-05 ES ES98957603T patent/ES2338389T3/es not_active Expired - Lifetime
- 1998-12-07 TW TW087118421A patent/TW443933B/zh not_active IP Right Cessation
1999
- 1999-05-13 CN CNB998167886A patent/CN1195523C/zh not_active Expired - Lifetime
- 1999-05-13 DE DE69919594T patent/DE69919594T2/de not_active Expired - Lifetime
- 1999-05-13 ES ES99923024T patent/ES2224661T3/es not_active Expired - Lifetime
- 1999-05-13 TR TR2002/00146T patent/TR200200146T2/xx unknown
- 1999-05-13 EP EP99923024A patent/EP1178833B1/de not_active Expired - Lifetime
- 1999-05-13 KR KR10-2001-7014474A patent/KR100462442B1/ko not_active Expired - Lifetime
- 1999-05-13 AT AT99923024T patent/ATE273714T1/de active
- 1999-05-13 BR BR9917299-2A patent/BR9917299A/pt not_active Application Discontinuation
- 1999-05-13 MX MXPA01011560A patent/MXPA01011560A/es active IP Right Grant
- 1999-05-13 HK HK02105901.5A patent/HK1044289B/en not_active IP Right Cessation
- 1999-05-13 JP JP2000617929A patent/JP2002544240A/ja active Pending
- 1999-05-13 PT PT99923024T patent/PT1178833E/pt unknown
- 1999-05-13 CA CA002373821A patent/CA2373821C/en not_active Expired - Lifetime
- 1999-05-13 IL IL14647099A patent/IL146470A0/xx unknown
- 1999-05-13 WO PCT/US1999/010596 patent/WO2000069469A1/en not_active Ceased
- 1999-05-13 AU AU39891/99A patent/AU757086B2/en not_active Expired
- 1999-05-13 DK DK99923024T patent/DK1178833T3/da active
- 1999-05-13 HU HU0201145A patent/HU230300B1/hu unknown
2001
- 2001-11-13 IL IL146470A patent/IL146470A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2002544240A (ja)	2002-12-24
TR200200146T2 (tr)	2002-06-21
DE69919594T2 (de)	2005-09-15
CA2309165A1 (en)	1999-05-14
HK1034678A1 (en)	2001-11-02
DE69919594D1 (de)	2004-09-23
AU757086B2 (en)	2003-01-30
JP4491560B2 (ja)	2010-06-30
HUP0201145A3 (en)	2004-05-28
KR20020012218A (ko)	2002-02-15
EP1178833B1 (de)	2004-08-18
ES2224661T3 (es)	2005-03-01
WO2000069469A1 (en)	2000-11-23
TR200002158T2 (tr)	2000-11-21
EP1178833A1 (de)	2002-02-13
HK1044289B (en)	2005-01-07
CN1284862A (zh)	2001-02-21
DK1178833T3 (da)	2004-11-22
JP2001521886A (ja)	2001-11-13
CN1354677A (zh)	2002-06-19
ES2338389T3 (es)	2010-05-06
HK1044289A1 (en)	2002-10-18
ATE455535T1 (de)	2010-02-15
IL135914A0 (en)	2001-05-20
CN1191060C (zh)	2005-03-02
CA2373821C (en)	2003-10-07
DK1028708T3 (da)	2010-05-03
TW443933B (en)	2001-07-01
KR100462442B1 (ko)	2004-12-17
IL146470A (en)	2010-12-30
WO1999022714A1 (en)	1999-05-14
EP1028708A4 (de)	2006-01-18
PT1178833E (pt)	2004-11-30
HU230300B1 (hu)	2015-12-28
KR100576986B1 (ko)	2006-05-10
BR9917299A (pt)	2002-07-09
EP1028708B1 (de)	2010-01-20
IL146470A0 (en)	2002-07-25
MXPA01011560A (es)	2002-06-04
EP1028708A1 (de)	2000-08-23
KR20010031836A (ko)	2001-04-16
HUP0201145A2 (hu)	2002-12-28
CA2373821A1 (en)	2000-11-23
DE69841463D1 (de)	2010-03-11
BR9813945A (pt)	2002-01-22
US6046244A (en)	2000-04-04
AU3989199A (en)	2000-12-05
CN1195523C (zh)	2005-04-06

Legal Events

Date

Code

Title

Description

2005-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1178833

Country of ref document: EP

Publication	Publication Date	Title
DE69919594D1 (de)	2004-09-23	Topische zusammensetzungen zur prostaglandin e1 abgabe
BE2014C001I2 (de)	2020-01-30
TR200202308T2 (tr)	2005-07-21	Prostaglandin E1 içeren tropikal bileşimler
IL160404A0 (en)	2004-07-25	Prostaglandin compositions and methods of treatment for male erectile dysfunction
DK0587858T3 (da)	2000-12-18	Væksthormonholdig proteinformulering
CA2309178A1 (en)	1999-05-14	Topical compositions for nsai drug delivery
NO934107D0 (no)	1993-11-12	Penetrasjonsfremmende substans
AU7977294A (en)	1995-05-01	Absorption enhancers for topical pharmaceutical formulations
CA2442479A1 (en)	2000-11-23	Topical compositions for prostaglandin e1 delivery
IE790098L (en)	1979-07-20	Solvent vehicle
ATE79277T1 (de)	1992-08-15	Eine pharmazeutische zusammensetzung angepasst an die transdermale applikation eines opioids.